Palbociclib, a specific inhibitor of CDK4/6, has been shown to provide a survival benefit in hormone receptorpositive advanced breast cancer; however, its resistance and related mechanisms are unclear.
Background
Palbociclib was the first inhibitor of cyclin-dependent kinase CDK4/6, developed by Pfizer, and approved to treat hormone receptor-positive (ER+) advanced breast cancer in February 2015 by the Food and Drug Administration [1] . Mechanistically, palbociclib inhibits ER+ breast cancer cell proliferation via impinging upon the G1-S cell cycle checkpoint [2] . However, development of therapeutic resistance is not uncommon in clinical treatment, and the mechanisms contributing to palbociclib resistance are still unclear. Thus, it is important to elucidate the detailed mechanisms, find potential targets, and explore combination therapy, to attenuate or predict palbociclib resistance.
Cancer stem cells are a small subset of cells which exist in tumor tissues and hold the potential of self-renewal and nondirectional differentiation, and have been proven to facilitate tumor progression, metastasis, and chemoresistance [3] . PI3K/ Akt/mTOR pathway has been shown to be involved in tumor stemness; Mecca et al. indicated that PP242 counteracts glioblastoma cell stemness properties by inhibiting mTORC2/AKT signaling [4] . Chen et al. demonstrated that PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppressed the stemness of colon cancer stem cells [5] . Furthermore, Du et al. showed that microRNA-451 regulated stemness of side population cells via PI3K/Akt/mTOR signaling in multiple myeloma [6] . Thus, targeting the PI3K/Akt/mTOR pathway has become a promising method to eliminate cancer stem cells. Everolimus, a mTOR inhibitor, has been approved to help treat breast cancer [7] and renal carcinoma [8] . However, it is still unclear whether everolimus attenuates ER+ breast cancer stemness.
In this study, we constructed palbociclib-resistant ER+ breast cancer cells (MCF-7-P), and found that MCF-7-P cells had stronger stemness and higher expression of drug resistancerelated genes ABCG2 and MDR1 relative to parental MCF-7 cells. Additionally, the PI3K/Akt/mTOR pathway was hyper-activated in MCF-7-P cells. Importantly, we found that everolimus attenuated the stemness of MCF-7-P cells and re-sensitized MCF-7-P cells to palbociclib. Notably, everolimus enhanced the efficiency of palbociclib on parental MCF-7 cells. Altogether, we demonstrated that everolimus, a mTOR inhibitor, could reverse palbociclib-resistance in ER+ human breast cancer cells by attenuating cell stemness through inhibiting the PI3K/Akt/ mTOR pathway.
Material and Methods

Cell culture and reagents
Human ER+ breast cancer cell line MCF-7 was purchased from the Chinese Academy of Sciences Cell Bank; DNA fingerprinting analysis was used to confirm its identity. MCF-7 cells were cultured in DMEM medium (Gibco) supplemented with 10% fetal bovine serum at 37°C under humidified air with 5% CO2. Palbociclib (Cat # 1579) and everolimus (Cat # S1120) were purchased from Selleck.
Construction of palbociclib resistant cells
We used a high concentration and short-time culturing method to develop palbociclib-resistant ER+ breast cancer cells (MCF-7-P). Briefly, 3×10
3 MCF-7 cells were seeded into 96-well plates and treated with 10 μM palbociclib. After 2 weeks, cell clones were collected and expanded to culture with 20 nM palbociclib. The resistance index was confirmed before using in further experiments.
Cell viability assay
Cells were digested and seeded in 96-well plates, and incubated overnight at 37°C in 5% CO 2 , followed by palbociclib (100 nM) treatment as well as treatment with or without everolimus for 24 hours, 48 hours, and 72 hours. MTT Cell Proliferation and Cytotoxicity Assay Kit (Cat # E606334, Sangon Biotech, Shanghai, China) was used to measure cell viability.
Cell spheroid formation assay
Cell spheroid formation assay was used to evaluate the stemness of cells with different treatment. Briefly, cells were digested and cultured in ultra-low attachment 24-well plates (Corning, Union City, CA, USA) at 1000 cells/well with MammoCult™ Human Medium Kit (Cat #05620, Stemcell Technologies, Vancouver, BC, Canada) for 10 days, followed by measuring spheroid number and size under a microscope fitted with a ruler (more than 50 μM). To evaluate the ability of self-renewal, spheroids were harvested, re-digested and re-cultured with the same condition aforementioned. This was repeated at least 3 times, and the rate of spheroid formation was examined.
Transwell migration assay
Transwell migration assay was used to detect the migration ability of cells. The detailed procedure was described in a previous study [9] .
ALDH1 activity assay
ALDEFLUOR™ Kit (Cat #KA3742, Stemcell Technologies) was used to evaluate cell populations with high ALDH1 activity according to the manufacturer's recommendation.
Flow cytometry assay
To examine the sub-population of stem cells in MCF-7 cells, cells were digested, re-suspended, and stained with the following antibodies: anti-CD44-PE, anti-CD24-APC, IgG1-PE, and IgG1-APC (BD), followed by cell sorting on another flow cytometer (BD C6), and analyzed with BD FACS Diva software.
Quantitative real-time PCR (qRT-PCR)
Quantitative real-time PCR (qRT-PCR) was performed to examine the mRNA level of transcripts. Briefly, cells were washed with phosphate buffer saline, and then FastPure Cell/Tissue Total RNA Isolation Kit (Cat #RC101, Vazyme Biotech Co., Ltd., Nanjing, China) was used to extract RNA from cells with different treatments, followed by synthesizing cDNA with HiScript II Q Select RT SuperMix for qPCR(+gDNA wiper) (Cat #R233-01, Vazyme Biotech Co., Ltd.). Then mRNA expression level was measured with AceQ Universal SYBR qPCR Master Mix (Cat #AQ201, Vazyme Biotech Co., Ltd.) on an ABI Prism 7500 Detection System (Applied Biosystems, Inc.). All samples, including negative control with template, were analyzed at least 3 times. Then mRNA relative expression was normalized to GAPDH expression, and determined using the 2 -DDct method.
Western blot
Cells were treated with RIPA Lysis Buffer (Cat #P0013B, Beyotime, Beijing, China), followed by determining protein concentration using Bradford Protein Assay Kit (Cat #P0006, Beyotime). Then 30 μg protein was separated by 10% SDS-PAGE. The protein was transferred onto PVDF membranes (BioRad). Blocking was carried out with 10% non-fat milk for 1.5 hours at 37°C. Then the membranes were washed with TBST for 15 minutes, 3 times, and incubated with the primary antibodies at 4°C overnight. The primary antibodies against ALDH1 (ab129815), Nanog (ab80892), ABCG2 (ab203397), MDR1 (ab3366), p-mTOR (ab84400), cleaved caspase-3 (ab32042), and cleaved PARP (ab32064) were purchased from Abcam. The pri-
, and vimentin (Cat #10366-1-AP) were purchased from Proteintech. Then membranes were washed with TBST for 15 minutes, 3 times, followed by incubating with HRP-labeled goat anti-rabbit IgG(H+L) (Cat #A0208, Beyotime), or HRP-labeled goat anti-mouse IgG(H+L) (Cat #A0216, Beyotime). ECL Plus (Cat #PE0010, Solarbio) was used to detect chemiluminescent signals in Bio-Rad ChemiDoc™ Touch (CM002554, Bio-Rad).
Statistical analysis
Data analysis was carried out using GraphPad Prism 5.01 (CA, USA), and presented as mean ± standard deviation. The significance of the differences between the groups were determined using one-way ANOVA with the Tukey-Kramer post-test.
Results were considered to be significant when the P value was less than 0.05.
Results
MCF-7-P cells exhibited palbociclib resistance and stronger stemness
We developed palbociclib-resistant MCF-7 cells (MCF-7-P). First, we confirmed the resistant characteristics of the MCF-7-P cells via cell viability assay. As shown in Figure 1A and 1B, palbociclib at 25 nM, 50 nM, and 100 nM significantly decreased cell viability of MCF-7 cells, but did not affected MCF-7-P cell viability. Consistently, we found the mRNA expression levels of 2 common drug resistance genes MDR1 and ABCG2 involved in resistance to CDK4/6 inhibitors [10] , were significantly upregulated in MCF-7-P cells ( Figure 1C, 1D ). Since cancer stem cells could confer drug resistance [11] , we investigated whether MCF-7-P cells had higher stemness. The qRT-PCR and western blot analysis ( Figure 1E , 1F) indicated that MCF-7-P cells displayed higher expression of stemness markers ALDH1 and Nanog [12, 13] . Notably, MCF-7-P cells displayed higher ALDH1 activity via ALDH1 activity assay ( Figure 1G ). Additionally, since CD44+/CD24-are well-acknowledged surface markers of breast cancer stem cells [14] , we examined the expression in MCF-7-P and MCF-7 cells and found the percentage of CD44+/CD24-cells in MCF-7-P cells was 42.3±0.62%, which was significantly higher than in the parental counterparts of MCF-7 cells which was 13.8% ± 0.65% ( Figure 1H ). Because previous studies indicated that non-adherent spheroids are highly enriched for cancer stem cells [15, 16] , we evaluated cell spheroid formation capability, and found that MCF-7-P cells exhibited stronger ability compared with MCF-7 cells, characterized as the increase of spheroid size and number ( Figure 1I, 1J) . Therefore, we established palbociclib-resistant MCF-7-P cells, and the MCF-7-P cells exhibited higher stemness.
PI3K/Akt/mTOR signaling was hyper-activated in MCF-7-P cells and mTOR inhibitor everolimus attenuated MCF-7-P cells stemness
Since PI3K/Akt/mTOR signaling is involved in cancer stem cells formation [17, 18] , we assumed that this signaling would be hyper-activated in MCF-7-P cells. As expected, the expression level of p-Akt and p-mTOR was significantly increased in MCF-7-P cells ( Figure 2A ). We examined whether mTOR 
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inhibitor everolimus could attenuate MCF-7-P cells stemness. The qRT-PCR and western blot analysis indicated that everolimus significantly decreased the expression of stemness markers ALDH1 and Nanog in a concentration dependent manner at 5 nM, 10 nM, and 20 nM ( Figure 2B, 2C) . And p-mTOR expression was suppressed in MCF-7-P cells with everolimus treatment ( Figure 2D ). Furthermore, ALDH1 activity was attenuated by everolimus treatment in MCF-7-P cells ( Figure 2E ). Additionally, everolimus decreased the cell spheroid formation ability of MCF-7-P cells in a concentration dependent manner ( Figure 2F, 2G) . Thus, our results suggested that everolimus could attenuate MCF-7-P cells stemness.
Everolimus exerted inhibition on MCF-7-P cells migration and epithelial-mesenchymal transition (EMT) process
We further investigated whether MCF-7-P cells had higher migration ability and whether everolimus could attenuate it. As shown in Figure 3A , Transwell migration assay showed that MCF-7-P cells had much higher migration ability than parental MCF-7 cells. Consistently, the expression of epithelial marker E-cadherin and mesenchymal marker vimentin was decreased or increased, respectively ( Figure 3B, 3C) . Remarkably, everolimus significantly decreased cell migration ability of MCF-7-P cells ( Figure 3D ), and attenuated epithelial-mesenchymal transition (EMT) process, characterized as the increase of E-cadherin expression and decrease of vimentin expression ( Figure 3E, 3F ).
. PI3K/Akt/mTOR signaling was hyper-activated in MCF-7-P cells and mTOR inhibitor everolimus attenuated MCF-7-P cells stemness. (A) Expression of p-Akt and p-mTOR was detected in MCF-7 and MCF-7-P cells. (B, C) Expression of stemness markers ALDH1 and Nanog was examined MCF-7-P cells with different concentrations of everolimus treatment. (D) p-mTOR expression was measured in MCF-7-P cells with different concentrations of everolimus treatment. (E) ALDH1 activity was determined in cells depicted in (D). (F, G) The cell spheroid formation ability was evaluated in cells depicted in (C
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Indexed Everolimus inhibited MCF-7-P spheroids viability, migration, EMT, and self-renewal ability Importantly, we determined whether everolimus could directly inhibit MCF-7-P spheroid progression. MCF-7-P cell spheroids were digested, re-suspended and seeded into 96-well plates;
after cells were attached, everolimus was added to the wells. After 24 hours, 48 hours, and 72 hours, cells viability was examined and showed that everolimus significantly decreased cells viability digested by cell spheroids ( Figure 4A ). Consistent results were obtained in Transwell migration and EMT process assays ( Figure 4B-4D) . Additionally, the self-renewal ability of 83 MCF-7-P spheroids were evaluated with everolimus (20 nM) treatment, and we found that the self-renewal ability of MCF-7-P spheroids was suppressed by everolimus treatment characterized as the decrease of spheroid-formation efficiency from the first to the third generation ( Figure 4E, 4F ).
Everolimus attenuated and enhanced palbociclib sensitivity of MCF-7 cells
Finally, we explored whether everolimus could attenuate palbociclib resistance in MCF-7-P cells. Cell viability assay indicated that everolimus rescued palbociclib resistance of MCF-7-P cells characterized as the decrease of cell viability and increase of Figure 5A , 5B). Meanwhile, the expression of drug resistance genes ABCG2 and MDR1 was decreased with combination use of everolimus and palbociclib ( Figure 5C, 5D) . Additionally, we continued investigating whether everolimus could enhance palbociclib sensitivity in parental MCF-7 cells. As expected, the palbociclib sensitivity of MCF-7 cells was enhanced by everolimus treatment, characterized as the additive inhibition on cell viability ( Figure 5E ), and additive promotion of the expression of apoptosis executors cleaved caspase-3 and cleaved PARP ( Figure 5F ). These results indicated that everolimus potentiates the anti-proliferative effects and attenuates resistance of palbociclib in ER+ breast cancer cells.
Discussion
Great successes with the clinical application of CDK4/6 inhibitor palbociclib have been reported for ER+ breast cancer, and clinical experiments in other tumors are in progress. However, development of drug resistance is common in the clinical setting, and thus it is necessary to elucidate the underlying mechanisms contributing to resistance, and explore combination treatment methods for patients with palbociclib resistance.
In the present study, palbociclib-resistant ER+ breast cancer cells were established, and we found that the PI3K/Akt/mTOR signaling was hyper-activated in MCF-7-P cells, indicating that palbociclib resistance was associated with PI3K/Akt/mTOR signaling, these results were consistent with a previous study [19] . However, resistance to CDK4/6 inhibitors could be contributed to other pathways, such as disruption of the RB pathway, as mediated by loss of the retinoblastoma tumor suppressor (RB), cyclin D1 and CDK6 amplification, and cyclin E-CDK2 activation [20] . Importantly, we demonstrated that the mTOR inhibitor everolimus could enhance palbociclib sensitivity and attenuated palbociclib resistance; these results indicated that everolimus might be used in combination therapy for ER+ breast cancer with or without palbociclib resistance.
Since cancer stem cells contributed to drug resistance and we identified that MCF-7-P cells had stronger stemness, this phenomenon was considered consistent with previous studies that indicated that transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion [21] , and that miR-302 inhibits the tumorigenicity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways [22] . Furthermore, we isolated MCF-7-P cells with stemness via cell spheroid formation assay, and the effects of everolimus on their progression and self-renewal ability were evaluated. Encouragingly, we showed that everolimus could inhibit MCF-7-P sphere cells viability, migration, and spheroid formation ability, indicating that everolimus could potentially kill breast cancer stem cells. To the best of our knowledge, this is the first study indicating that everolimus could kill breast cancer stem cells. However, it is unclear whether everolimus holds similar effects in other tumors, which should be explored in future works.
Conclusions
These findings demonstrated that acquired CDK4/6 resistance was associated with PI3K/Akt/mTOR signaling and increasing of cells stemness and that these effects were attenuated by everolimus treatment. Our results provide the basis for the next steps in pre-clinical investigation on combination or sequential therapeutic strategies with everolimus and palbociclib in the clinic.
